TRVI News and Press, Trevi Therapeutics Inc. From 02/20/20

NEW HAVEN, Conn., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced that management will...

NEW HAVEN, Conn., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (“Trevi”), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced the ele...

Today, we will be studying why Trevi Therapeutics ( TRVI ) is an attractive investment for 2020. Company overview Trevi Therapeutics is a clinical-stage company focused on the development of nalbuphine ER to treat multiple serious and chronic neurologically mediated conditions . Nalbuph...

Trevi Therapeutics (NASDAQ: TRVI ): Q3 GAAP EPS of -$0.41 beats by $0.11 . More news on: Trevi Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

Advancement of Nalbuphine ER in Clinical Development for Three Indications Cash Position of $63.5 Million Expected to Fund Operations Through At Least Q1 2021 NEW HAVEN, Conn., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceut...

NEW HAVEN, Conn., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced that management will...

The NASDAQ Biotechnology Index (INDEXNASDAQ: NBI ) had a rocky time last week, starting at 3,467.3 points and reaching a low of 3,396.02 points on Thursday (November 7). By Friday (November 8), the index had recovered slightly to reach 3,454.53 points as of 1:59 p.m. EST. On Tuesday (...

For an equity market that has hit all-time highs on multiple occasions during this year, one would think that investors would be salivating over IPOs for a chance to "get in from the beginning" and bidding them higher in the process. The reality, though, is that IPOs have been one of the more ...

NEW HAVEN, Conn., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced that Jennifer L. Go...

Quick Take BELLUS Health ( BLU ) has filed to raise gross proceeds of $60 million from a U.S. IPO, according to an F-10 registration statement . The firm is developing therapeutics for chronic cough and other hypersensitization disorders. BLU is in the middle of Phase 2 trials for its l...